In 1959, I reported on the use of oxytetracycline hydrochloride (Terramycin)-polymyxin B sulfate powder* in 5,691 patients without significant allergic reactions.1 Since that report, I have had the opportunity to use this preparation on more than 5,500 additional patients with dermatological problems similar to those in the previous report.
Together with 5,691 cases in a previous report, the present series of 5,500 cases brings to over 11,000 the total number of patients treated by me with a powder containing 3.31% oxytetracycline hydrochloride and 0.144% polymyxin B sulfate in U.S.P. lactose. In not a single case has there been observed a definite instance of eczematous dermatitis from the topical use of oxytetracycline hydrochloride or of polymyxin B sulfate.
With the powder preparation studied, allergic eczematous dermatitis from the topical use of oxytetracycline hydrochloride or polymyxin B sulfate would seem to be virtually nonexistent.Sherwood W. Barefoot, M.D., 1030
BAREFOOT SW. Topical Oxytetracycline-Polymyxin—Further Observations: Use of Powder Without Allergic Eczematous Reactions. Arch Dermatol. 1962;86(2):236. doi:10.1001/archderm.1962.01590080106018
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: